Aim To reseach the promotive role of passing intmportal veinous chemotherapy combined with hyperbaric oxygen after hepatocellular carcinoma resection.Methods Sixty-five HCC patients were classified into two groups wit...Aim To reseach the promotive role of passing intmportal veinous chemotherapy combined with hyperbaric oxygen after hepatocellular carcinoma resection.Methods Sixty-five HCC patients were classified into two groups with randomly. One group was performed byintraportal veinous chemotherpy, the other group was performed by intraportal veinous chemotherapy combined with hyperbaric oxygen. Among 65 HCC cases, 43 patientswere tested with hepatic function; 54 and 27 patients weretested in serum sIL-2R, T-SOD and Mn-SOD activityrespectively; Of the 48 patients were analysed relativefactors with recurrence, 23 HCC patients (HBO group) and25 patients (Non-HBO group) were given intraportal veinouschemotherapy for four courses with FMC scheme and werecompared.Results There were no obvious difference in serumbiochemical items sIL-2R, T-SOD and Mn-SOD activitybefore and after one week of the chemotherapy in the HBOgroup (P > 0.05 ). There were obvious differences ofbiochemical items (X^2= 9.01, P < 0.01 ), PT (X^2=4.22, P < 0.05 ) , sIL-2R (t= 5.74, P < 0.01), T-SOD (t=5.735, P <0.01 ) and Mn-SOD (t=8.66, P< 0.01) activity in serum between the HBO group and Non-HBO group after the chemotherapy. Although recurrcencerelating to the size of HCC (X^2= 8.18, P < 0.01 ),impairment of hepatic function (X^2= 4.70, P < 0.05) anddegree of hepatic cirrhosis (X^2= 3.95, P < 0.05) wasobvious, yet HBO group was higher than Non-HBO group inreducing recurrence (X^2= 5.30, P < 0.05).Conclusion hatraportal veinous regular chemotherapycombined with HBO can significantly reduce recurrrnce after HCC resection.展开更多
文摘Aim To reseach the promotive role of passing intmportal veinous chemotherapy combined with hyperbaric oxygen after hepatocellular carcinoma resection.Methods Sixty-five HCC patients were classified into two groups with randomly. One group was performed byintraportal veinous chemotherpy, the other group was performed by intraportal veinous chemotherapy combined with hyperbaric oxygen. Among 65 HCC cases, 43 patientswere tested with hepatic function; 54 and 27 patients weretested in serum sIL-2R, T-SOD and Mn-SOD activityrespectively; Of the 48 patients were analysed relativefactors with recurrence, 23 HCC patients (HBO group) and25 patients (Non-HBO group) were given intraportal veinouschemotherapy for four courses with FMC scheme and werecompared.Results There were no obvious difference in serumbiochemical items sIL-2R, T-SOD and Mn-SOD activitybefore and after one week of the chemotherapy in the HBOgroup (P > 0.05 ). There were obvious differences ofbiochemical items (X^2= 9.01, P < 0.01 ), PT (X^2=4.22, P < 0.05 ) , sIL-2R (t= 5.74, P < 0.01), T-SOD (t=5.735, P <0.01 ) and Mn-SOD (t=8.66, P< 0.01) activity in serum between the HBO group and Non-HBO group after the chemotherapy. Although recurrcencerelating to the size of HCC (X^2= 8.18, P < 0.01 ),impairment of hepatic function (X^2= 4.70, P < 0.05) anddegree of hepatic cirrhosis (X^2= 3.95, P < 0.05) wasobvious, yet HBO group was higher than Non-HBO group inreducing recurrence (X^2= 5.30, P < 0.05).Conclusion hatraportal veinous regular chemotherapycombined with HBO can significantly reduce recurrrnce after HCC resection.
